Health Condition 1: J22- Unspecified acute lower respiratory infection
Conditions
Interventions
Intervention1: Injection Ceftriaxone, Sulbactum , Disodium EDTA and Colistin to the patients with Multi drug resistant ventilator associated pneumonia: Injection Ceftriaxone, Sulbactum , Disodium ED
Sponsors
SGRD Hospital
Eligibility
Inclusion criteria
Inclusion criteria: 1) Age > 18 years 2) Primary diagnosis of VAP based on the the presence of ventilator associated events (VAE) which are consisted of [Ventilator associated condition (VAC)- worsened oxygenation + Increase in positive expiratory pressure by 3 cm or increase in FiO2 by 2% , Infection related ventilator associated condition (IVAC)- fever >38C or hypothermia 12000 and antibiotics for least 4 days and positive microbiological result.] 3) Positive culture of MDR ( Acinetobacter baumanii, Klebsiella pneumoniae) 4) Patients who will be (meropenem and AAE resistant). 5) Hospitalization for more than 5 days. 6) Subjects with clinically significant cardiovascular, renal, hepatic, gastrointestinal conditions, neurological, psychiatric, respiratory, other severely immunocompromised, hematological or malignant disease, history of uncontrolled diabetes mellitus, HIV and hepatitis-B and other condition which may interfere with the assessment will be carefully assessed and any significant information will be recorded and reported.
Exclusion criteria
Exclusion criteria: 1) Patients who will receive treatment for less than 72hrs. 2) Subjects with history of resistance to any of the investigational drugs, history of hypersensitivity, allergic response or any contraindications to penicillin, cephalosporin or carbapenem groups of drugs, history of hearing loss 3) Participation in any clinical study during data collection period. 4) Pregnant or lactating mother
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Clinical, Bacteriological and safety response of the patientsTimepoint: 1st day of beginning of antibiotics then 3rd,5th,7th,10th and 14th day | — |
Secondary
| Measure | Time frame |
|---|---|
| Cost effectiveness in terms of money spent on antibioticsTimepoint: 10th day and 14th day | — |
Countries
India
Contacts
Public ContactDr Jonny Dhawan
Sri Guru Ram Das Institute of Medical Sciences and Research
Outcome results
None listed